Saturday 17 October 2026
Export SNGX’s income statement to Excel — free account
Soligenix Inc.
SNGX Healthcare Biotechnology
Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.
0.35
0.01
−2.78%
Follow SNGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (241.65%) | (326.88%) | (235.50%) | (165.10%) |
+8 more TTM periods Free account |
|
| (125.95%) | (149.35%) | (121.75%) | (102.63%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(157.37%) | (370.87%) | (214.80%) | (149.62%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.61) | (1.06) | (1.98) | (2.25) | |
Free Cash Flow |
(9.74) | (10.78) | (10.27) | (9.76) | |
Capital Expenditures |
— | — | (0.01) | 0.00 | |
| Other line items | |||||
Cash ROIC |
(59.20%) | (118.18%) | (77.66%) | (53.84%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.95 | 0.98 | 0.93 | 0.87 | |
Depreciation/Fixed assets |
0.62 | 0.48 | 0.36 | 0.41 | |
Capex/Depreciation |
0.00 | 0.00 | (1.84) | (1.22) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.61) | (1.06) | (1.98) | (2.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates